NDA 219713 · Nuvation
Ibtrozi
Taletrectinib Adipate · Oral
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Jun 11, 2025: To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jun 11, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
109
61 serious, 15 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 21, 2026.
IBTROZI ® (taletrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) [see Dosage and Administration ( 2.1 )] . IBTROZI is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC). ( 1 )
Mechanism: Taletrectinib is an inhibitor of tyrosine kinase ROS1, including ROS1 resistance mutations. Taletrectinib also showed inhibitory effects on tropomyosin receptor kinases (TRKs) TRKA, TRKB, and TRKC. Fusion proteins that include ROS1 domains can drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to unconstrained cell proliferation. Taletrectinib inhibited growth of cancer cells expressing ROS1 fusion genes and mutations. In mice subcutaneously implanted with tumors harboring ROS1 fusions, including the G2032R mutation, administration of taletrectinib...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 16, 2026 Supplement 4 · Efficacy OrphanLetterLabel
- Jun 11, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- IBTROZI · TALETRECTINIB ADIPATE EQ 200MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Taletrectinib Adipate" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea38
- nausea27
- fatigue17
- vomiting15
- dizziness12
- decreased appetite10
- hepatic function abnormal8
- pyrexia8
- rash8
- constipation7
- disease progression7
- dysphagia7
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 26 |
| 2026 | 83 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Nuvation
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.